Cubist Systematic Strategies, LLC Iveric Bio, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $1.14 Million - $1.72 Million	43,304 Added 105.87%	84,207 $3.31 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $177,271 - $233,197	-9,495 Reduced 18.84%	40,903 $995,000
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $1.41 Million - $1.96 Million	-81,747 Reduced 61.86%	50,398 $1.08 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $796,086 - $1.57 Million	-84,690 Reduced 39.06%	132,145 $2.37 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $1.98 Million - $4.1 Million	216,835 New	216,835 $2.09 Million

Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $300,117 - $415,717	-24,701 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $1.88 Million - $2.55 Million	-135,769 Reduced 84.61%	24,701 $413,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $1.01 Million - $2.49 Million	142,273 Added 781.85%	160,470 $2.61 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $103,540 - $130,472	18,197 New	18,197 $115,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $6.6 $53,057 - $114,437	-17,339 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $49,069 - $146,341	17,339 New	17,339 $60,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.